Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14335463 | 1.00 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL492385 | 1.00 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL28593017 | 0.95 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4799589 | 0.88 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL18386438 | 0.88 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL18047943 | 0.77 | — | — | |
| SCHEMBL8686895 | 0.75 | — | — | |
| SCHEMBL2272941 | 0.70 | — | — | |
| SCHEMBL25363741 | 0.69 | KMT2A (0.37) | — | |
| SCHEMBL18598380 | 0.65 | CHRM2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | claimed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | claimed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | claimed |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | COILED THERAPEUTICS, INC. | 2025-06-26 | — | — | US | claimed |
| WO-2025072722-A1 | METHODS FOR TREATING CANCERS ASSOCIATED WITH TRANSFORMING ACIDIC COILED-COIL PROTEINS | A2A PHARMACEUTICALS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2025060911-A1 | SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都奥睿药业有限公司 | 2025-03-27 | — | — | WO | claimed |
| EP-4499625-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | A2A Pharmaceuticals, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240374590-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | COILED THERAPEUTICS, INC. | 2024-11-14 | — | — | US | claimed |
| CN-118878535-A | Substituted pyridotriazole compound, preparation method and application thereof | 成都奥睿药业有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | claimed |
| EP-3200789-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2017-08-09 | — | — | EP | claimed |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | claimed |
| WO-2016053772-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-04-07 | — | — | WO | claimed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | claimed |
| US-20140178304-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-26 | — | — | US | claimed |
| CN-103889974-A | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals | TAKEDA PHARMACEUTICAL | 2014-06-25 | — | — | CN | claimed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | claimed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | claimed |
| EP-0094018-B1 | 4-ARYL-4-PIPERIDINECARBINOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-03-09 | — | — | EP | claimed |
| EP-0094018-A2 | 4-Aryl-4-piperidinecarbinols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-11-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | ALDH1A1 3601/4885 |
| US-20240374590-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NTPCR, PTPRC, NFATC1 | ALDH1A1 1208/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | ALDH1A1 2086/4885 |
| US-20140178304-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | PDE5A, PDE3B, PDE3A | ALDH1A1 328/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | ALDH1A1 2710/4885 |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NTPCR, PTPRC, NFATC1 | ALDH1A1 1208/4885 |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK1, IRAK2 | ALDH1A1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.